The top 10 pharma milestones of the year to date.
Cost effectiveness agency critical of real world evidence plans
German watchdog criticises EMA adaptive pathways approval
Companies still need to provide a compelling case for efficacy
The EMA’s Adaptive Pathways: are safety concerns exaggerated?